Cargando…

Is Interstitial Chemotherapy with Carmustine (BCNU) Wafers Effective against Local Recurrence of Glioblastoma? A Pharmacokinetic Study by Measurement of BCNU in the Tumor Resection Cavity

The effectiveness of carmustine (BCNU) wafers on local recurrence of glioblastoma (GBM) remains contentious. We investigated the accumulating high-dose effects of BCNU released from the wafers on the survival of GBM patients by measuring BCNU concentration in the resection cavity of GBM over time. B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohnishi, Takanori, Yamashita, Daisuke, Inoue, Akihiro, Suehiro, Satoshi, Ohue, Shiro, Kunieda, Takeharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139119/ https://www.ncbi.nlm.nih.gov/pubmed/35624954 http://dx.doi.org/10.3390/brainsci12050567

Ejemplares similares

Safety and efficacy of carmustine (BCNU) wafers for metastatic brain tumors
por: Ene, Chibawanye I., et al.
Publicado: (2016)

Double-edged Sword in the Placement of Carmustine (BCNU) Wafers along the Eloquent Area: A Case Report
por: Kuramitsu, Shunichiro, et al.
Publicado: (2014)

Interstitial chemotherapy with biodegradable BCNU (Gliadel(®)) wafers in the treatment of malignant gliomas
por: Bota, Daniela A, et al.
Publicado: (2007)

Importance of biomarkers in glioblastomas patients receiving local BCNU wafer chemotherapy
por: Urbschat, Steffi, et al.
Publicado: (2017)

Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.
por: Jones, A. L., et al.
Publicado: (1990)

Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma
por: MATSUMURA, Hideaki, et al.
Publicado: (2018)

STMO-15 THE CLINICAL IMPACT OF VENTRICULAR OPENING IN THE IMPLANTATION OF BCNU WAFERS FOR MALIGNANT GLIOMA
por: Matsuda, Ryosuke, et al.
Publicado: (2022)

BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors
por: Reithmeier, Thomas, et al.
Publicado: (2010)

STMO-01 Cerebral edema and perioperative epilepsy due to placement of BCNU wafer for malignant glioma
por: Fujii, Yu, et al.
Publicado: (2020)

COT-3 Exosomal microRNA expression signature in blood and cerebrospinal fluid of glioblastoma patients
por: Yamashita, Daisuke, et al.
Publicado: (2021)

An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) with BCNU Wafers in the Surgical Management of Primary Glioblastoma
por: Watts, Colin, et al.
Publicado: (2021)

A Multicenter Phase I/II Study of the BCNU Implant (Gliadel (®) Wafer) for Japanese Patients with Malignant Gliomas
por: AOKI, Tomokazu, et al.
Publicado: (2014)

BCNU (Bis-chloroethylnitrosourea, Carmustine) Toxicity Presented as a Large Pleural Effusion 60 Days Post Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma
por: Dvorak, Shelby N, et al.
Publicado: (2019)

In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.
por: Mulcahy, R. T., et al.
Publicado: (1981)

In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.
por: Tannock, I. F.
Publicado: (1980)

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
por: Johnston, S. R., et al.
Publicado: (1998)

Cerebral Infarction Related to Carmustine Wafers in Glioblastoma: A Case Report
por: Nakada, Mitsutoshi, et al.
Publicado: (2014)

In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole.
por: Siemann, D. W., et al.
Publicado: (1984)

rhGM-CSF ameliorates neutropenia in patients with malignant glioma treated with BCNU.
por: Rampling, R., et al.
Publicado: (1994)

Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas.
por: Kaaijk, P., et al.
Publicado: (1996)

MLTI-11. IMPLANTABLE POLYMERIC BCNU AS AN ADJUNCT TO SURGERY FOR METASTATIC INTRACRANIAL DISEASE
por: Ryken, Timothy, et al.
Publicado: (2019)

Significance of Glioma Stem-Like Cells in the Tumor Periphery That Express High Levels of CD44 in Tumor Invasion, Early Progression, and Poor Prognosis in Glioblastoma
por: Nishikawa, Masahiro, et al.
Publicado: (2018)

The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.
por: Zulian, G. B., et al.
Publicado: (1989)

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.
por: Wedge, S. R., et al.
Publicado: (1996)

Superoxide Enhances the Antitumor Combination of AdMnSOD Plus BCNU in Breast Cancer
por: Sun, Wenqing G., et al.
Publicado: (2010)

Advanced Gastric Carcinoma Chemotherapy with Cisplatin, Mitomycin C, BCNU, and 5-Fluorouracil in Combination
por: Kim, Re Hwe, et al.
Publicado: (1987)

ANGI-2 Identification and functions of CD44 as a predictor for bevacizumab-resistant glioblastoma to optimally treat the tumor with bevacizumab
por: Inoue, Akihiro, et al.
Publicado: (2021)

Successful immunotherapy with micrococcus, BCG or related polysaccharides on L1210 leukaemia after BCNU chemotherapy.
por: Verloes, R., et al.
Publicado: (1981)

Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients
por: Jungk, Christine, et al.
Publicado: (2016)

TB-04 TERT PROMOTER MUTATION AS A SUSCEPTIBLE MOLECULAR MARKER OF BCNU LOCAL THERAPY
por: Miyake, Shigeta, et al.
Publicado: (2019)

Carmustine Wafer Implantation at the Era of Standardized Chemoradiation Protocol
por: Roux, Alexandre, et al.
Publicado: (2019)

Identification of a Prognostic Microenvironment-Related Gene Signature in Glioblastoma Patients Treated with Carmustine Wafers
por: Manini, Ivana, et al.
Publicado: (2022)

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma
por: Nishikawa, Masahiro, et al.
Publicado: (2021)

Elevated expression of Dickkopf-1 increases the sensitivity of human glioma cell line SHG(44 )to BCNU
por: Zhou, Youxin, et al.
Publicado: (2010)

Improving thermal stability and efficacy of BCNU in treating glioma cells using PAA-functionalized graphene oxide
por: Lu, Yu-Jen, et al.
Publicado: (2012)

Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas
por: Azzalin, Alberto, et al.
Publicado: (2017)

Hypoxia-induced phenotypic transition from highly invasive to less invasive tumors in glioma stem-like cells: Significance of CD44 and osteopontin as therapeutic targets in glioblastoma
por: Nishikawa, Masahiro, et al.
Publicado: (2021)

Symptomatic cerebral vasospasm in the setting of carmustine wafer placement for glioblastoma: A case presentation and review of literature
por: Khan, Maheen Qamar, et al.
Publicado: (2020)

High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.
por: Mbidde, E. K., et al.
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_3sat8qsh8j69eemejdvtm3glnh